Award
National Cancer Institute 1R21CA292338-01
Tumor-Activated Dual Payload-Drug Conjugates
Recipient
Washington State University, Pullman, WA
Award Amount
$393,401.00
Ceiling
$393,401.00
Awarded
July 01, 2024
Identifier
1R21CA292338-01
Development of a PSMA-targeted dual drug conjugate for improved treatment of metastatic castration-resistant prostate cancer, focusing on tumor-site activation and dual payload delivery to overcome drug resistance and tumor heterogeneity.
Description
This project aims to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC). The strategy involves tumor-site activation and release of two chemotherapeutic payloads, enhancing efficacy over single-drug conjugates. The work includes assessing cargo release in prostate tumor cells and evaluating potency in cell lines, utilizing innovative drug delivery strategies such as PSMA-ligand internalization, acid-labile linkers, and dual drugs with different mechanisms.